PANCREATIC DUCTAL ADENOCARCINOMA

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…

This study tests a new immunotherapy for adults with advanced pancreatic cancer. The treatment uses a special protein and virus to help the immune system kill cancer cells, combined with an antibody called ezabenlimab. The goal is to find a safe dose and see if the combination ca…

This study tests a new combination for people with pancreatic cancer that cannot be surgically removed or has spread. It uses a light-activated drug (verteporfin) to make tumors more sensitive to immunotherapy (pembrolizumab), alongside standard chemotherapy. The goal is to see i…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This phase II trial is testing a combination of two experimental drugs (AZD0171 and durvalumab) plus standard chemotherapy in 126 people with advanced pancreatic cancer. The goal is to see if the combo is safe and helps patients live longer. Participants must have metastatic dise…

This study tests different combinations of immunotherapy drugs given before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if these treatments can help the immune system fight the cancer better and improve outcomes. About 76 participan…

This study tests whether adding the experimental drug navlimetostat to standard chemotherapy can help people with a specific type of advanced pancreatic cancer (one with an MTAP gene deletion) live longer or slow tumor growth. About 470 adults who have not had prior treatment for…

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This study tests if washing the abdomen with distilled water or saline right after removing a pancreatic tumor can help patients live longer. About 845 adults having surgery for pancreatic or related cancers are randomly assigned to one of three groups: washing with saltwater, wa…

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…

This early-phase trial tests whether transferring healthy gut bacteria from donor stool can help control pancreatic cancer. Ten patients scheduled for tumor-removal surgery will receive the transplant to see if it is safe and affects the disease. The study is currently suspended.

This study tests whether a combination of three drugs (paricalcitol, hydroxychloroquine, and losartan) can safely modify the supportive tissue around pancreatic tumors before surgery. About 20 adults with resectable pancreatic cancer will take these drugs for at least 4 weeks bet…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study tests whether giving chemotherapy both before and after surgery helps people with pancreatic cancer live longer compared to chemotherapy only after surgery. About 378 patients with resectable pancreatic cancer will be randomly assigned to one of two treatment schedules…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study was designed to see if giving two chemotherapy drugs (gemcitabine and capecitabine) after surgery could help people with pancreatic cancer stay cancer-free longer. It was for patients who had already received chemotherapy before surgery. However, the trial was withdraw…

This phase 2 trial tests a new drug called ZN-c3 combined with the chemotherapy gemcitabine in 12 people with advanced pancreatic cancer that has worsened after platinum-based treatment. The goal is to see if the combination is safe and can slow cancer growth. Participants take Z…

This study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…

This study tests whether a special heat probe, inserted through an endoscope, can help people with inoperable pancreatic cancer live longer. About 108 participants will either receive the heat treatment plus standard care, or standard care alone. The trial is currently on hold, s…

This early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…

This study tests a combination of two experimental drugs (AGEN1423 and botensilimab) with or without standard chemotherapy in people with advanced pancreatic cancer that has worsened after at least one prior treatment. The goal is to see if the combination can shrink tumors or sl…

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This early-stage trial tests a new drug called BMS-986484, alone or with another drug (nivolumab), in people with advanced solid tumors like lung, colon, pancreatic, stomach, and head/neck cancers. The main goal is to check safety and find the right dose. About 213 participants w…

This early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…

This study tests a new drug called futibatinib combined with standard immunotherapy and chemotherapy in people with advanced esophageal or pancreatic cancer. The goal is to see if the combination can shrink tumors and control the disease. About 53 adults who have not had prior tr…

This early-phase trial tests whether adding two immune-boosting drugs (canakinumab and tislelizumab) to standard chemotherapy can safely shrink pancreatic tumors before surgery. Nine adults with resectable or borderline resectable pancreatic cancer will receive the combination. T…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This study tests a new drug called chiauranib combined with two standard chemotherapy drugs as a first treatment for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival. …

This early study tests whether adding three cholesterol-lowering drugs (atorvastatin, ezetimibe, and evolocumab) to standard chemotherapy can slow or stop pancreatic cancer growth. Cancer cells need lots of cholesterol to grow, and this approach aims to starve them. The trial inc…

This study tests whether a 6-month program of exercise tracking and nutrition coaching is practical and acceptable for people with pancreatic cysts that raise cancer risk. Twenty-four participants will use a Fitbit and meet with counselors to increase activity and improve diet. T…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests giving a single dose of chemotherapy directly into the liver artery before standard surgery and systemic chemo for localized pancreatic cancer. The goal is to see if this approach is safe and feasible in 20 patients. Researchers hope it may help prevent the cance…

This early-phase trial tests an investigational drug called ABBV-400 in about 300 adults with advanced solid tumors, including liver, pancreatic, breast, and ovarian cancers. The study aims to see if the drug can shrink tumors and to check for side effects. Participants receive A…

This study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…

This phase 2 trial is testing the safety and effectiveness of glipizide, a standard diabetes drug, for lowering blood sugar in people with pancreatic cancer. The study includes 29 participants with active pancreatic cancer and high blood sugar. Researchers will measure blood suga…

This phase II trial tests whether switching from one chemotherapy regimen to another early on, before surgery, can help remove pancreatic cancer more completely. It includes patients with resectable, borderline resectable, or locally advanced unresectable pancreatic cancer. The s…

This phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…

This early-phase trial is testing whether a personalized cancer vaccine, combined with an immunotherapy drug (atezolizumab) and chemotherapy, is safe for people with pancreatic cancer that has been surgically removed. The vaccine is made specifically for each patient based on the…

This phase IIb trial tests whether adding ATRA (a vitamin A derivative) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with locally advanced pancreatic cancer live longer without their cancer growing. About 170 participants will receive either the combo…

This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boo…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This early-phase trial tests whether adding a targeted drug called ivosidenib to standard chemotherapy can help shrink pancreatic tumors before surgery. About 16 people with resectable pancreatic cancer that has a specific gene mutation (IDH1) will receive the drug combination fo…

This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aim…

This study tests an artificial intelligence model called PANDAPro that helps doctors spot pancreatic cancer on regular CT scans. Researchers will compare how well the AI finds cancers versus standard reading, and see if it catches tumors that were missed. The goal is to make scre…

This study is working on a new way to detect pancreatic cancer early using a simple urine and blood test. Researchers are collecting samples from 3500 people, both with and without pancreatic disease, to see if a panel of biomarkers can accurately identify cancer. The goal is to …

This study looks at whether measuring certain substances in bile and blood can more accurately diagnose cancer in people with bile duct blockages. Researchers will compare these new tests with standard methods in 500 adults undergoing a procedure called ERCP. The goal is to find …

This study aimed to test a new two-step PET imaging method to better detect cancers that produce a substance called CA19-9, such as pancreatic, bladder, and gastrointestinal tumors. The plan was to give patients an antibody followed by a radioactive tracer to highlight cancer cel…

This early-phase trial at Memorial Sloan Kettering is testing whether a special PET scan using an experimental tracer called 18F-FAC can show how much of the standard chemotherapy drug gemcitabine is taken up by pancreatic tumors. About 30 people with pancreatic ductal adenocarci…

This study tests an 8-week program of nutrition advice, exercise, and psychological support for people with pancreatic or esophageal cancer before they have surgery. The goal is to see if patients can complete the program and if it helps them prepare for surgery. Only 9 patients …

This study looks at whether ketorolac, a common anti-inflammatory drug, is safe and can help stabilize or increase weight in people with advanced pancreatic cancer who are experiencing cachexia (severe weight loss). About 28 participants will take the drug four times daily for fi…

This study explores whether ultrasound images analyzed by a special computer program can accurately measure the size of liver tumors in people with pancreatic or gastrointestinal cancer that has spread to the liver. Participants will have both a routine contrast-enhanced CT scan …

This study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …

This study looks at people with pancreatic cancer to find genetic factors that may increase risk. Researchers will collect medical and family history and test for gene mutations. The goal is to build a tool that can better identify who is at risk for this disease. 271 participant…

This registry collects information from 2000 people who have had pancreatic surgery for benign or malignant tumors. Researchers track complications and long-term results to understand what works best. The goal is to improve quality of care and support future research.

This study enrolls 200 people with pancreatic cancer across Ontario. Researchers collect tumor tissue, blood, and stool samples to perform genetic sequencing and grow mini-tumors in the lab. The goal is to see if this detailed analysis helps more patients receive a treatment matc…

This study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…

This study creates a registry for people with BRCA or PALB2 gene mutations who have pancreatic cancer, along with their close relatives. Researchers will collect medical information, blood samples, and tumor tissue to better understand why pancreatic cancer develops in this group…

This study aims to develop a way to predict which patients with advanced pancreatic cancer will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 100 participants before and during treatment. By analyzing these samples, they hope to cr…